Investigation of 305 patients with myelodysplastic syndromes and 20q deletion for associated cytogenetic and molecular genetic lesions and their prognostic impact

British Journal of Haematology

Volumn 164, Issue 6, 2014, Pages 822-833

  Bacher, Ulrike ^a   Haferlach, Torsten ^a   Schnittger, Susanne ^a   Zenger, Melanie ^a   Meggendorfer, Manja ^a   Jeromin, Sabine ^a   Roller, Andreas ^a   Grossmann, Vera ^a   Krauth, Maria Theresa ^a,b   Alpermann, Tamara ^a   Kern, Wolfgang ^a   Haferlach, Claudia ^a  

^a MLL MUNICH LEUKEMIA LABORATORY   (Germany)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

20q deletion; Cytogenetics; Myelodysplastic syndromes; SRSF2 mutation; U2AF1 mutation

Indexed keywords

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; ASXL1 GENE; CHROMOSOME 20Q; CHROMOSOME ABERRATION; CHROMOSOME BANDING PATTERN; CHROMOSOME DELETION; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; CYTOPATHOLOGY; DNA FLANKING REGION; EYA2 GENE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC DISORDER; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; MUTATIONAL ANALYSIS; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; PTPRT GENE; SF3B1 GENE; SPLICEOSOME; SRSF2 GENE; SURVIVAL RATE; U2AF1 GENE;

20Q DELETION; CYTOGENETICS; MYELODYSPLASTIC SYNDROMES; SRSF2 MUTATION; U2AF1 MUTATION;

ADULT; AGED; AGED, 80 AND OVER; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 20; CYTOGENETICS; FEMALE; GENOMICS; HUMANS; MALE; MIDDLE AGED; MUTATION; MYELODYSPLASTIC SYNDROMES; PROGNOSIS;

EID: 84896726052     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12710     Document Type: Article

References (41)

1. Bacher, U., Haferlach, C., Kern, W., Haferlach, T. & Schnittger, S. (2008) Prognostic relevance of FLT3-TKD mutations in AML: the combination matters-an analysis of 3082 patients. Blood, 111, 2527-2537.
2. Bacher, U., Haferlach, T., Schnittger, S., Zenger, M., Meggendorfer, M., Roller, A., Grossmann, V., Krauth, M., Jeromin, S., Alpermann, T., Kohlmann, A., Kern, W. & Haferlach, C. (2013) Myelodysplastic syndromes (MDS) with 20q deletion show a high frequency of associated cytogenetic and molecular lesions with an association to U2AF1, SRSF2, and prognostically Adverse ASXL1 mutations. Blood (ASH Annual Meeting Abstracts), abstract 657a.
3. Bench, A.J., Nacheva, E.P., Hood, T.L., Holden, J.L., French, L., Swanton, S., Champion, K.M., Li, J., Whittaker, P., Stavrides, G., Hunt, A.R., Huntly, B.J., Campbell, L.J., Bentley, D.R., Deloukas, P. & Green, A.R. (2000) Chromosome 20 deletions in myeloid malignancies: reduction of the common deleted region, generation of a PAC/BAC contig and identification of candidate genes. UK Cancer Cytogenetics Group (UKCCG). Oncogene, 19, 3902-3913.
4. Bilhou-Nabera, C. (2000) del(20q) in myeloid malignancies. Atlas of Genetics and Cytogenetics in Oncology and Haematology, December 2000. http://AtlasGeneticsOncology.org/Anomalies/del20qID1040.html
5. Braun, T., de Botton, S., Park, S., Beyne-Rauzy, O., Coiteux, V., Sapena, R., Lazareth, A., Leroux, G., Guenda, K., Cassinat, B., Fontenay, M., Vey, N., Guerci, A., Dreyfus, F., Bordessoule, D., Stamatoullas, A., Castaigne, S., Terre, C., Eclache, V., Fenaux, P. & Ades, L. (2011) Characteristics and outcome of myelodysplastic syndromes (MDS) with isolated 20q deletion: a report on 62 cases. Leukemia Research, 35, 863-867.
6. Brunning, R., Orazi, A., Germing, U., Le Beau, M.M., Porwit, A., Baumann, I., Vardiman, J.W. & Hellstrom-Lindberg, E. (2008) Myelodysplastic syndromes. In: WHO classification of tumours of haematopoietic and lymphoid tissues (ed. by S. Swerdlow, E. Campo, N. Lee Harris, E.S. Jaffe, S.A. Pileri, H. Stein, J. Thiele & J.W. Vardiman ), pp. 87-93. International Agency for Research on Cancer, Lyon.
7. Dicker, F., Haferlach, C., Kern, W., Haferlach, T. & Schnittger, S. (2007) Trisomy 13 is strongly associated with AML1/RUNX1 mutations and increased FLT3 expression in acute myeloid leukemia. Blood, 110, 1308-1316.
8. Gelsi-Boyer, V., Brecqueville, M., Devillier, R., Murati, A., Mozziconacci, M.J. & Birnbaum, D. (2012) Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases. International Journal of Hematologic Oncology, 5, 12.
9. Graubert, T.A., Shen, D., Ding, L., Okeyo-Owuor, T., Lunn, C.L., Shao, J., Krysiak, K., Harris, C.C., Koboldt, D.C., Larson, D.E., McLellan, M.D., Dooling, D.J., Abbott, R.M., Fulton, R.S., Schmidt, H., Kalicki-Veizer, J., O'Laughlin, M., Grillot, M., Baty, J., Heath, S., Frater, J.L., Nasim, T., Link, D.C., Tomasson, M.H., Westervelt, P., DiPersio, J.F., Mardis, E.R., Ley, T.J., Wilson, R.K. & Walter, M.J. (2012) Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nature Genetics, 44, 53-57.
10. Greenberg, P., Cox, C., Le Beau, M.M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., Ohyasshiki, K., Toyama, K., Aul, C., Mufti, G. & Bennett, J.M. (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood, 89, 2079-2088.
11. Greenberg, P.L., Tuechler, H., Schanz, J., Sanz, G., Garcia-Manero, G., Sole, F., Bennett, J.M., Bowen, D., Fenaux, P., Dreyfus, F., Kantarjian, H., Kuendgen, A., Levis, A., Malcovati, L., Cazzola, M., Cermak, J., Fonatsch, C., Le Beau, M.M., Slovak, M.L., Krieger, O., Luebbert, M., Maciejewski, J., Magalhaes, S.M., Miyazaki, Y., Pfeilstocker, M., Sekeres, M., Sperr, W.R., Stauder, R., Tauro, S., Valent, P., Vallespi, T., van de Loosdrecht, A.A., Germing, U. & Haase, D. (2012) Revised international prognostic scoring system (IPSS-R) for myelodysplastic syndromes. Blood, 120, 2454-2465.
12. Gupta, R., Soupir, C.P., Johari, V. & Hasserjian, R.P. (2007) Myelodysplastic syndrome with isolated deletion of chromosome 20q: an indolent disease with minimal morphological dysplasia and frequent thrombocytopenic presentation. British Journal of Haematology, 139, 265-268.
13. Haferlach, C., Rieder, H., Lillington, D.M., Dastugue, N., Hagemeijer, A., Harbott, J., Stilgenbauer, S., Knuutila, S., Johansson, B. & Fonatsch, C. (2007) Proposals for standardized protocols for cytogenetic analyses of acute leukemias, chronic lymphocytic leukemia, chronic myeloid leukemia, chronic myeloproliferative disorders, and myelodysplastic syndromes. Genes Chromosomes and Cancer, 46, 494-499.
14. Haferlach, C., Bacher, U., Kohlmann, A., Schindela, S., Alpermann, T., Kern, W., Schnittger, S. & Haferlach, T. (2011) CDKN1B, encoding the cyclin-dependent kinase inhibitor 1B (p27), is located in the minimally deleted region of 12p abnormalities in myeloid malignancies and its low expression is a favorable prognostic marker in acute myeloid leukemia. Haematologica, 96, 829-836.
15. Hiller, B., Bradtke, J., Balz, H. & Rieder, H. (2005) CyDAS: a cytogenetic data analysis system. Bioinformatics, 21, 1282-1283.
16. Huh, J., Tiu, R.V., Gondek, L.P., O'Keefe, C.L., Jasek, M., Makishima, H., Jankowska, A.M., Jiang, Y., Verma, A., Theil, K.S., McDevitt, M.A. & Maciejewski, J.P. (2010) Characterization of chromosome arm 20q abnormalities in myeloid malignancies using genome-wide single nucleotide polymorphism array analysis. Genes Chromosomes and Cancer, 49, 390-399.
17. Jeromin, S., Haferlach, T., Grossmann, V., Alpermann, T., Kowarsch, A., Haferlach, C., Kern, W. & Schnittger, S. (2013) High frequencies of SF3B1 and JAK2 mutations in refractory anemia with ring sideroblasts associated with marked thrombocytosis strengthen the assignment to the category of myelodysplastic/myeloproliferative neoplasms. Haematologica, 98, e15-e17.
18. Kanagal-Shamanna, R., Yin, C.C., Miranda, R.N., Bueso-Ramos, C.E., Wang, X.I., Muddasani, R., Medeiros, L.J. & Lu, G. (2013) Therapy-related myeloid neoplasms with isolated del(20q): comparison with cases of de novo myelodysplastic syndrome with del(20q). Cancer Genetics, 206, 42-46.
19. Kern, W., Haferlach, C., Schnittger, S. & Haferlach, T. (2010) Clinical utility of multiparameter flow cytometry in the diagnosis of 1013 patients with suspected myelodysplastic syndrome: correlation to cytomorphology, cytogenetics, and clinical data. Cancer, 116, 4549-4563.
20. Kurtin, P.J., Dewald, G.W., Shields, D.J. & Hanson, C.A. (1996) Hematologic disorders associated with deletions of chromosome 20q: a clinicopathologic study of 107 patients. American Journal of Clinical Pathology, 106, 680-688.
21. Li, T., Xue, Y., Wu, Y. & Pan, J. (2006) FISH studies identify the i(20q-) anomaly as a der(20)del(20)(q11q13)idic(20)(p11). Genes Chromosomes and Cancer, 45, 536-539.
22. Ligon, A.H., DeAngelo, D.J., Atkins, L. & Dal, C.P. (2005) Isochromosome of a deleted 20q may be a relatively common abnormality in myeloid malignancies. Cancer Genetics and Cytogenetics, 162, 89-91.
23. Löffler, H., Rastetter, J. & Haferlach, T. (2010) Atlas of Clinical Hematology, 6th edn. Springer, Heidelberg.
24. van de Loosdrecht, A.A., Alhan, C., Bene, M.C., la Porta, M.G., Drager, A.M., Feuillard, J., Font, P., Germing, U., Haase, D., Homburg, C.H., Ireland, R., Jansen, J.H., Kern, W., Malcovati, L., te Marvelde, J.G., Mufti, G.J., Ogata, K., Orfao, A., Ossenkoppele, G.J., Porwit, A., Preijers, F.W., Richards, S.J., Schuurhuis, G.J., Subira, D., Valent, P., van der Velden, V., Vyas, P., Westra, A.H., de Witte, T.M., Wells, D.A., Loken, M.R. & Westers, T.M. (2009) Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes. Haematologica, 94, 1124-1134.
25. Meggendorfer, M., Roller, A., Haferlach, T., Eder, C., Dicker, F., Grossmann, V., Kohlmann, A., Alpermann, T., Yoshida, K., Ogawa, S., Koeffler, H.P., Kern, W., Haferlach, C. & Schnittger, S. (2012a) SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). Blood, 120, 3080-3088.
26. Meggendorfer, M., Haferlach, C., Kern, W., Haferlach, T. & Schnittger, S. (2012b) The two mutation hot spots Ser34 and Gln157 in U2AF1 show different occurrence, correlation and clinical features in myeloid malignancies: an analysis of 785 cases. Blood, 120, 3789a.
27. Mufti, G.J., Bennett, J.M., Goasguen, J., Bain, B.J., Baumann, I., Brunning, R., Cazzola, M., Fenaux, P., Germing, U., Hellstrom-Lindberg, E., Jinnai, I., Manabe, A., Matsuda, A., Niemeyer, C.M., Sanz, G., Tomonaga, M., Vallespi, T. & Yoshimi, A. (2008) Diagnosis and classification of myelodysplastic syndrome: international Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts. Haematologica, 93, 1712-1717.
28. Mullier, F., Daliphard, S., Garand, R., Dekeyser, M., Cornet, Y., Luquet, I., Talmant, P., Richebourg, S., Jamar, M., Dogne, J.M., Chatelain, C., Michaux, L. & Chatelain, B. (2012) Morphology, cytogenetics, and survival in myelodysplasia with del(20q) or ider(20q): a multicenter study. Annals of Hematology, 91, 203-213.
29. Qian, J., Yao, D.M., Lin, J., Qian, W., Wang, C.Z., Chai, H.Y., Yang, J., Li, Y., Deng, Z.Q., Ma, J.C. & Chen, X.X. (2012) U2AF1 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome. PLoS ONE, 7, e45760.
30. Saunders, K., Czepulkowski, B., Sivalingam, R., Hayes, J.P., Aldouri, M., Sekhar, M., Cummins, M., Ho, A. & Mufti, G.J. (2005) Isochromosome of a deleted 20q: a rare but recurrent chromosome abnormality in myelodysplastic syndromes. Cancer Genetics and Cytogenetics, 156, 154-157.
31. Schanz, J., Steidl, C., Fonatsch, C., Pfeilstocker, M., Nosslinger, T., Tuechler, H., Valent, P., Hildebrandt, B., Giagounidis, A., Aul, C., Lubbert, M., Stauder, R., Krieger, O., Garcia-Manero, G., Kantarjian, H., Germing, U., Haase, D. & Estey, E. (2011) Coalesced multicentric analysis of 2, 351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system. Journal of Clinical Oncology, 29, 1963-1970.
32. Schanz, J., Tuchler, H., Sole, F., Mallo, M., Luno, E., Cervera, J., Granada, I., Hildebrandt, B., Slovak, M.L., Ohyashiki, K., Steidl, C., Fonatsch, C., Pfeilstocker, M., Nosslinger, T., Valent, P., Giagounidis, A., Aul, C., Lubbert, M., Stauder, R., Krieger, O., Garcia-Manero, G., Faderl, S., Pierce, S., Le Beau, M.M., Bennett, J.M., Greenberg, P., Germing, U. & Haase, D. (2012) New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after mds derived from an international database merge. Journal of Clinical Oncology, 30, 820-829.
33. Schnittger, S., Schoch, C., Dugas, M., Kern, W., Staib, P., Wuchter, C., Loffler, H., Sauerland, C.M., Serve, H., Buchner, T., Haferlach, T. & Hiddemann, W. (2002) Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood, 100, 59-66.
34. Schnittger, S., Schoch, C., Kern, W., Mecucci, C., Tschulik, C., Martelli, M.F., Haferlach, T., Hiddemann, W. & Falini, B. (2005) Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood, 106, 3733-3739.
35. Schnittger, S., Eder, C., Jeromin, S., Alpermann, T., Fasan, A., Grossmann, V., Kohlmann, A., Illig, T., Klopp, N., Wichmann, H.E., Kreuzer, K.A., Schmid, C., Staib, P., Peceny, R., Schmitz, N., Kern, W., Haferlach, C. & Haferlach, T. (2013) ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome. Leukemia, 27, 82-91.
36. Shetty, S. & Roland, B. (2008) Isoderivative chromosome 20 in bone marrow: three new cases. Cancer Genetics and Cytogenetics, 184, 72-73.
37. Thol, F., Friesen, I., Damm, F., Yun, H., Weissinger, E.M., Krauter, J., Wagner, K., Chaturvedi, A., Sharma, A., Wichmann, M., Gohring, G., Schumann, C., Bug, G., Ottmann, O., Hofmann, W.K., Schlegelberger, B., Heuser, M. & Ganser, A. (2011) Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. Journal of Clinical Oncology, 29, 2499-2506.
38. Thol, F., Kade, S., Schlarmann, C., Loffeld, P., Morgan, M., Krauter, J., Wlodarski, M.W., Kolking, B., Wichmann, M., Gorlich, K., Gohring, G., Bug, G., Ottmann, O., Niemeyer, C.M., Hofmann, W.K., Schlegelberger, B., Ganser, A. & Heuser, M. (2012) Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood, 119, 3578-3584.
39. Weisser, M., Kern, W., Schoch, C., Hiddemann, W., Haferlach, T. & Schnittger, S. (2005) Risk assessment by monitoring expression levels of partial tandem duplications in the MLL gene in acute myeloid leukemia during therapy. Haematologica, 90, 881-889.
40. Westers, T.M., Ireland, R., Kern, W., Alhan, C., Balleisen, J.S., Bettelheim, P., Burbury, K., Cullen, M., Cutler, J.A., la Porta, M.G., Drager, A.M., Feuillard, J., Font, P., Germing, U., Haase, D., Johansson, U., Kordasti, S., Loken, M.R., Malcovati, L., te Marvelde, J.G., Matarraz, S., Milne, T., Moshaver, B., Mufti, G.J., Ogata, K., Orfao, A., Porwit, A., Psarra, K., Richards, S.J., Subira, D., Tindell, V., Vallespi, T., Valent, P., van der Velden, V., de Witte, T.M., Wells, D.A., Zettl, F., Bene, M.C. & van de Loosdrecht, A.A. (2012) Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European leukemianet working group. Leukemia, 26, 1730-1741.
41. Wu, S.J., Kuo, Y.Y., Hou, H.A., Li, L.Y., Tseng, M.H., Huang, C.F., Lee, F.Y., Liu, M.C., Liu, C.W., Lin, C.T., Chen, C.Y., Chou, W.C., Yao, M., Huang, S.Y., Ko, B.S., Tang, J.L., Tsay, W. & Tien, H.F. (2012) The clinical implication of SRSF2 mutation in patients with myelodysplastic syndrome and its stability during disease evolution. Blood, 120, 3106-3111.